Dublin-based Actavis PLC said Friday that it is seeking approval from the US Food and Drug Administration (FDA) to sell a generic version of Gilead Sciences Inc.’s pulmonary arterial hypertension (PAH) drug. The company confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the agency seeking approval …